Status:
COMPLETED
De Novo Lipogenesis, Lipid and Carbohydrate Metabolism in Non-alcoholic Fatty Liver Disease
Lead Sponsor:
University of California, San Francisco
Collaborating Sponsors:
Touro University
American Diabetes Association
Conditions:
Non-alcoholic Fatty Liver Disease
Diabetes
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
The worldwide epidemic of obesity is paralleled with increased cases of non-alcoholic liver disease (liver fat accumulation) and diabetes. Fat belongs in the adipose tissue, and if excess fat accumula...
Detailed Description
Non-alcoholic fatty liver disease (NAFLD) is the most common liver ailment in developed countries. Fatty liver - steatosis - affects up to one third of the population. Its prevalence is rising and see...
Eligibility Criteria
Inclusion
- In the steatotic subjects, steatosis will be diagnosed by MRS or liver biopsy in which \>33% of the hepatocytes will contain fat. Non-steatotic controls will not have biopsies since they are not medically warranted; thus, to ensure they do not have steatosis they will undergo MRS during screening and have a total lipid: unsuppressed water \< 0.05.
Exclusion
- Habitual consumption of alcohol \> 20 g/day for men and 10 g/day for women
- Confirmed HIV-1 infection, Hgb \<13 g/dL for males and \<12 g/dL for females
- Abnormal hepatitis B or C serology
- Diabetes or current use of any antidiabetic or hypolipidemic agents
- Presence of metal-containing substances in the body (e.g. a fragment in the eye, aneurysm clips, ear implants, spinal nerve stimulators or a pacemaker)
- Weight over 350 pounds or severe claustrophobia, which would preclude the MR studies
- Any condition that would preclude adherence to the protocol or the ability to provide informed consent
- Change in body weight \>5% within the preceding 6 months (by self-report)
- Known intolerance, allergy or hypersensitivity to fructose
- Pregnancy or lactation (for women); OR
- Any other condition that, in the opinion of the investigators, would put the subject at risk.
Key Trial Info
Start Date :
September 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 12 2012
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT00714129
Start Date
September 1 2007
End Date
October 12 2012
Last Update
February 17 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Touro University
Vallejo, California, United States, 94592